DOL Extends Comment Period for Pharmacy Benefit Manager Transparency Rule

You might care about this because the Department of Labor (DOL) has announced an extension for public comments on a proposed rule. This rule is about making Pharmacy Benefit Managers (PBMs) more transparent. PBMs and related service providers would need to tell self-insured group health plans about the money they receive. This disclosure is important for complying with the Employee Retirement Income Security Act (ERISA). The original proposed rule aimed to help plans understand how much PBMs get paid. This allows plans to check if their contracts are fair and reasonable. A new law called the Consolidated Appropriations Act of 2026 (CAA, 2026) was passed recently. This new law changed ERISA. It added specific rules for PBMs. These new rules include more disclosure requirements. They also require PBMs to pass on rebates from drug companies to the health plans. Because of these changes, the DOL needs more time to hear from the public. They want to know if the proposed rule should be updated to match the new law. The deadline for comments is now April 15, 2026. The DOL's main goal remains to improve transparency in how PBMs are compensated. This should help lower prescription drug costs and ensure fairness in healthcare. The department believes the new law supports these goals. They want feedback on how to make the rule work best with the new legal requirements. This includes reducing complexity and making sure the transparency goals are still met. This document is particularly interesting because it shows how new laws can quickly impact ongoing government efforts. The DOL had already proposed a rule to bring more openness to Pharmacy Benefit Manager fees. Then, Congress passed a new law, the Consolidated Appropriations Act of 2026, which also focused on PBM transparency. This new law changed existing ERISA rules. The DOL is now taking extra steps to get public feedback on how its proposed rule should align with these new legal requirements. This quick adaptation highlights the government's commitment to addressing prescription drug costs and PBM practices. It also gives the public a direct opportunity to help shape important regulations. This process can make sure that rules are effective and work well with the latest laws. Many different groups of people will find this legal document highly relevant. Self-insured group health plans, which are often employers, should pay close attention. They are the ones who contract with PBMs and will benefit from increased transparency. Pharmacy Benefit Managers and their related brokerage or consulting firms also need to be aware of these changes. These are the organizations whose compensation practices are being reviewed. Healthcare industry professionals, especially those focused on drug pricing and benefits, will find this information key. Attorneys specializing in ERISA or healthcare law will need to understand these updates to advise their clients. Policy researchers and advocates working to lower drug prices will also be interested. Finally, employees who get their health coverage through self-insured plans might find this relevant, as these efforts aim to control healthcare costs.